FGFR-TKI resistance in cancer: current status and perspectives.

Article Details

Citation
Copy to clipboard

Yue S, Li Y, Chen X, Wang J, Li M, Chen Y, Wu D

FGFR-TKI resistance in cancer: current status and perspectives.

J Hematol Oncol. 2021 Feb 10;14(1):23. doi: 10.1186/s13045-021-01040-2.

PubMed ID
33568192 [ View in PubMed
]
Abstract

Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved great success in tumor-targeted therapy. However, resistance to FGFR-TKI has become a concern. Here, we review the mechanisms of FGFR-TKI resistance in cancer, including gatekeeper mutations, alternative signaling pathway activation, lysosome-mediated TKI sequestration, and gene fusion. In addition, we summarize strategies to overcome resistance, including developing covalent inhibitors, developing dual-target inhibitors, adopting combination therapy, and targeting lysosomes, which will facilitate the transition to precision medicine and individualized treatment.

DrugBank Data that Cites this Article

Drugs